The STAT6 inhibitory peptide can educate the immune system away from developing an allergic response.
Dr. Elizabeth Fixman developed STAT6-IP, a chimeric inhibitory peptide with the ability to enter cells and disrupt activity of the STAT6 transcription factor. STAT6 has been show to inhibit aberrant Th2 responses in the airways of preclinical models of respiratory syncytial virus infection (Eur J Immunol 2014) and asthma (J Immunol 2007; Clin Exp Allergy 2011; Mucosal Immunol 2015).
The latter publication by Dr. Christine McCusker received significant media attention.
This work was also selected for one of the top ten scientific breakthroughs of 2015 selected by Québec Science and Dr. Christine McCusker was nominated as the Feb 2016 Researcher of the Month by Canadians for Health Research.